From GlobeNewswire:

RAPT Therapeutics, Inc. will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 at 9:00 a.m. Pacific Time. The clinical-stage company aims to discover, develop, and commercialize oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology.

The company RAPT Therapeutics is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. This includes two unique drug candidates targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively.

Investor Contact: Sylvia Wheeler [email protected] Media Contact: Aljanae Reynolds [email protected]



Read more: RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan